Markers of Adjuvant Safety 2013

Scientific Committee

Brigitte Autran
Université Pierre & Marie Curie
Paris, France
Steven Black
University of Cincinnati
Ohio, USA
William Egan
Novartis
USA
Bernard Fritzell
co-Chairman
IABS Human Vaccine Committee
Giuseppe Del Giudice
Novartis
Siena, Italy
Martin Friede
WHO
Geneva, Switzerland
Nathalie Garçon
GlaxoSmithKline Biologicals
Rixensart, Belgium
Michel Goldman
IMI
Brussels, Belgium
Ian Gust
University of Melbourne
Australia
Paul-Henri Lambert
University of Geneva
Switzerland
David Lewis
University of Surrey
United Kingdom
Pieter Neels
EMA
United Kingdom
Jim Robertson
NIBSC
United Kingdom
Rebecca Sheets
NIH/NIAID
USA
Emanuelle Trannoy
Sanofi Pasteur
Lyon, France
David Wood
WHO
Geneva, Switzerland

Meeting management:

Dodet Bioscience
Lyon, France

Objectives of the Workshop

This workshop aims to:

Review the latest developments in adjuvants
Identify the potential and limits of new technologies and how to use them to define biomarkers of vaccine efficacy
Pinpoint gaps and bottlenecks in the evaluation and prediction of efficacy and safety of adjuvanted vaccines
Identify the potential and limits of animal models
Identify the most promising pathways and areas where research could be strengthened

Outcome and Deliverables

The intended outcome of the presentations and discussions is to identify areas for further research.
A summary report of the meeting will be published.

Organized by

Become an IABS Member

Add to Calendar http://markers-of-adjuvant-safety-2013.iabs.org/ 18-04-2013 07:30:00 19-04-2013 15:45:00 15 International Workshop - Adjuvant Safety Predictive Markers of Adjuvant Safety and Immunology Rockville, Maryland, USA IABS markers-of-adjuvant-safety-2013@dodetbioscience.com false

Gold Sponsors

CSL

Silver Sponsors